Patents by Inventor Ananthachari Srinivasan

Ananthachari Srinivasan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7015306
    Abstract: Peptide analogs of neurotensin are disclosed which are resistant to enzymatic degradation and which retain high binding affinity for neurotensin receptors. Pharmaceutical compositions of these compounds are useful for diagnostic and therapeutic purposes.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: March 21, 2006
    Assignee: BioSynthema, Inc.
    Inventors: Ananthachari Srinivasan, Jack L. Erion, Michelle A. Schmidt
  • Publication number: 20050191240
    Abstract: Peptide analogs of neurotensin are disclosed which are resistant to enzymatic degradation and which retain high binding affinity for neurotensin receptors. Pharmaceutical compositions of these compounds are useful for diagnostic and therapeutic purposes.
    Type: Application
    Filed: December 21, 2001
    Publication date: September 1, 2005
    Inventors: Ananthachari Srinivasan, Jack Erion, Michelle Schmidt
  • Patent number: 6866837
    Abstract: Compounds and methods for the diagnosis and treatment of tumors, including breast and prostate tumors and metastases thereof using radiolabelled peptides that bind to GRP receptors. The peptides are Bombesin analogs wherein the first and optionally the third amino acid are modified.
    Type: Grant
    Filed: February 6, 2003
    Date of Patent: March 15, 2005
    Assignee: Mallinckrodt Inc.
    Inventors: Jean-Claude Reubi, Wout A. Breeman, Ananthachari Srinivasan
  • Publication number: 20040106548
    Abstract: Conformational constraints in diagnostic and therapeutic agents in peptides have been introduced by utilization of disulfide bonds and amide cyclizations. These constraints are responsible for altering the stability and specificity of these receptor-targeted agents. Conformationally constrained peptides containing secondary and primary amines, ethers, thioethers, amidines, esters and other functionalities have been synthesized. Methods are disclosed which incorporate multiple features of the above functionalities in the macrocyclic ring of the peptides.
    Type: Application
    Filed: July 11, 2003
    Publication date: June 3, 2004
    Inventors: Michelle A Schmidt, Jack L Erion, Ananthachari Srinivasan
  • Patent number: 6664367
    Abstract: Stable analogs of cyclic peptides containing disulfide linkages are disclosed. The disulfide linkage is modified by one of four methods: (a) sulfide contraction, (b) isosteric substitution, (c) thioketal expansion, or (d) alkylation expansion. In sulfide contraction the disulfide bond (—S—S—) is replaced with a monosulfide bond (—S—) in which a bifunctional effector molecule, such as a ligand or chemotoxic agent, is bound to the new peptide linkage. In isosteric substitution, one sulfur atom is replaced with a carbon atom and at least one of the carbon atoms at the modified site is a bifunctional effector molecule. In thioketal expansion, an alkylidene unit (—CR1C2—) is inserted between the two sulfur atoms. In alkylation expansion, an alkyl moiety of from C2 to C3, is inserted between the two sulfur atoms.
    Type: Grant
    Filed: July 21, 1994
    Date of Patent: December 16, 2003
    Assignee: Biosynthema, Inc.
    Inventors: Raghavan Rajagopalan, Ananthachari Srinivasan, Leon R. Lyle
  • Publication number: 20030224998
    Abstract: Compounds and methods for the diagnosis and treatment of tumors, including breast and prostate tumors and metastases thereof using radiolabelled peptides that bind to GRP receptors. The peptides are Bombesin analogs wherein the first and optionally the third amino acid are modified.
    Type: Application
    Filed: February 6, 2003
    Publication date: December 4, 2003
    Applicant: Mallinckrodt Inc.
    Inventors: Jean-Claude Reubi, Wout A. Breeman, Ananthachari Srinivasan
  • Patent number: 6132697
    Abstract: A radiopharmaceutical capable of localizing at a site of thrombus containing activated platelets within a mammalian body is provided wherein the radiopharmaceutical comprises a linear peptidomimetic containing ligand capable of specifically binding to the GPIIb/IIIa integrin receptor of platelets in the thrombus and a radionuclide covalently bound to the peptidomimetic containing ligand. The ligand compositions of the invention are provided complexed with a selected metal radionuclide to form a diagnostic or therapeutic radiopharmaceutical to image a site of thrombus or provide radiotherapy to the site of thrombus, respectively.
    Type: Grant
    Filed: June 5, 1997
    Date of Patent: October 17, 2000
    Assignee: G. D. Searle & Co.
    Inventors: Ananthachari Srinivasan, Larry P. Feigen, Daniel Lee Flynn, Jeffery Alan Zablocki, Philip Needleman, Michelle A. Schmidt
  • Patent number: 5830431
    Abstract: This invention relates to radiolabeled peptide compositions for radiopharmaceutical use and, more specifically, to radiolabeled peptides for diagnostic or therapeutic use having an unmodified carboxy terminal amino acid. The radiopharmaceutical composition may be used for targeting a selected biological site. The radiolabeled peptide is characterized by having its carboxy terminal amino acid in its carboxylic acid form and the peptide is coupled to a diagnostic or therapeutic radionuclide by a chelating agent. The radiopharmaceutical composition preferably comprises a radiolabeled peptide selected from the group consisting of somatostatin, an analog of somatostatin, a derivative of somatostatin and peptides capable of binding to the somatostatin receptor, where the peptide is coupled to a diagnostic or therapeutic radionuclide by a chelating agent has its carboxy terminal amino acid in its carboxylic acid form.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 3, 1998
    Assignee: Mallinckrodt Medical, Inc.
    Inventors: Ananthachari Srinivasan, Mary Marmion Dyszlewski, Joseph E. Bugaj, Jack L. Erion
  • Patent number: 5804157
    Abstract: This invention relates to radiolabeled peptide compositions for radiopharmaceutical use and, more specifically, to radiolabeled peptides for diagnostic or therapeutic use having an unmodified carboxy terminal amino acid. The radiopharmaceutical composition may be used for targeting a selected biological site. The radiolabeled peptide is characterized by having its carboxy terminal amino acid in its carboxylic acid form and the peptide is coupled to a diagnostic or therapeutic radionuclide by a chelating agent. The radiopharmaceutical composition preferably comprises a radiolabeled peptide selected from the group consisting of somatostatin, an analog of somatostatin, a derivative of somatostatin and peptides capable of binding to the somatostatin receptor, where the peptide is coupled to a diagnostic or therapeutic radionuclide by a chelating agent has its carboxy terminal amino acid in its carboxylic acid form.
    Type: Grant
    Filed: December 12, 1997
    Date of Patent: September 8, 1998
    Assignee: Mallinckrodt Medical, Inc.
    Inventors: Ananthachari Srinivasan, Mary Marmion Dyszlewski, Joseph E. Bugaj
  • Patent number: 5798444
    Abstract: Compositions and methods of incorporating ligand precursors and ligands at any location within a peptide during peptide synthesis are disclosed. Derivatives of 2,4,5-triaminopentanoic acid and .gamma.-aminoglutamic acid are selectively incorporated into the peptide during solid phase or liquid phase synthesis, depending upon the choice of protecting groups. Ligand synthesis may then be completed at a later time to produce N.sub.3 S, N.sub.2 S.sub.2, and EDTA type chelating agents.
    Type: Grant
    Filed: September 5, 1996
    Date of Patent: August 25, 1998
    Inventors: T. Jeffrey Dunn, Ananthachari Srinivasan
  • Patent number: 5736120
    Abstract: A method for radiolabelling peptides using polyaminocarboxylate ligands having suitable protecting groups such that they can be added to peptides by standard solid phase or solution phase peptide synthetic chemistry and can be deproteced using standard cleavage/deprotection reagents and produce the peptide/chelate conjugate as a high purity monoaddition product is provided. The cleaved and deprotected ligand-peptide molecules can then be labeled with lanthanide or actinide radionuclides. The protected polyaminocarboxylate ligands form mono-anhydrides or mono-active esters under solid phase or solution phase conditions and permit only the desired monoaddition chelate-peptide conjugate to be formed.
    Type: Grant
    Filed: June 7, 1996
    Date of Patent: April 7, 1998
    Inventor: Ananthachari Srinivasan
  • Patent number: 5734011
    Abstract: Compositions and methods of incorporating ligand precursors and ligands at any location within a peptide during peptide synthesis are disclosed. Derivatives of 2,4,5-triaminopentanoic acid and .gamma.-aminoglutamic acid are selectively incorporated into the peptide during solid phase or liquid phase synthesis, depending upon the choice of protecting groups. Ligand synthesis may then be completed at a later time to produce N.sub.3 S, N.sub.2 S.sub.2, and EDTA type chelating agents.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 31, 1998
    Assignee: Mallinckrodt Medical, Inc.
    Inventors: T. Jeffrey Dunn, Ananthachari Srinivasan
  • Patent number: 5681927
    Abstract: Chelated radionuclide compositions are provided for conjugation to polypeptides and carbohydrates. The resulting conjugates may be used in diagnosis and therapy.
    Type: Grant
    Filed: June 11, 1993
    Date of Patent: October 28, 1997
    Assignee: NeoRx Corporation
    Inventors: Alan R. Fritzberg, Sudhakar Kasina, Tripuraneni N. Rao, Jean-Luc VanderHeyden, Ananthachari Srinivasan
  • Patent number: 5656253
    Abstract: The present invention relates particularly to novel pyridine based nitrogen-sulfur ligands that are suitable for complexing with a radionuclide, and are useful as general imaging agents for diagnostic purposes, novel aminothiol ligands that are suitable for complexing with a radionuclide, and are useful as general imaging agents for diagnostic purposes, and amide-thiolate ligands having improved metal chelate formation kinetics. The amide-thiolate ligands include an amine which converts to a vinylogous amide upon complexation, thereby providing rapid complexation and thermodynamic stability. The ligands may be used for post formed labeling of biological substances for use in the fields of diagnosis and therapy.
    Type: Grant
    Filed: June 7, 1994
    Date of Patent: August 12, 1997
    Assignee: Mallinckrodt Medical, Inc.
    Inventors: Raghavan Rajagopalan, Ananthachari Srinivasan, Jean-Luc Vanderheyden
  • Patent number: 5653958
    Abstract: The present invention relates particularly to novel imidazole based nitrogen-sulfur ligands that are suitable for complexing with a radionuclide, and are useful as general imaging agents for diagnostic purposes.
    Type: Grant
    Filed: April 10, 1995
    Date of Patent: August 5, 1997
    Assignee: Mallinckrodt Medical, Inc.
    Inventors: Raghavan Rajagopalan, Ananthachari Srinivasan
  • Patent number: 5633372
    Abstract: The present invention relates particularly to novel heterocycle based nitrogen-sulfur ligands that are suitable for complexing with a radionuclide, and are useful as general imaging agents for diagnostic purposes.
    Type: Grant
    Filed: April 10, 1995
    Date of Patent: May 27, 1997
    Assignee: Mallinckrodt Medical, Inc.
    Inventors: Raghavan Rajagopalan, Ananthachari Srinivasan
  • Patent number: 5625075
    Abstract: The present invention provides metal chelating compounds, to chelates and chelate-targeting agent conjugates formed from the chelating compounds, and to methods for making and using these compositions. The chelating compounds incorporate two nitrogen atoms and three sulfur atoms ("N.sub.2 S.sub.3 "), two nitrogen atoms and four sulfur atoms ("N.sub.2 S.sub.4 "), or three nitrogen atoms and three sulfur atoms ("N.sub.3 S.sub.3 "). Metals, and metal oxides, capable of being chelated by the compounds include those that are radionuclides, such as .sup.99m Tc and .sup.186/188 Re.The targeting agent portion of the chelate-targeting agent conjugates provided includes antibodies, peptides, hormones, enzymes and biological response modifiers. Methods for making the conjugates are provided and encompass the addition of a metal, or metal oxide, to a chelating compound prior to attachment to a targeting agent as well as subsequent to the attachment.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: April 29, 1997
    Assignee: NeoRx Corporation
    Inventors: Ananthachari Srinivasan, Alan R. Fritzberg, David S. Jones
  • Patent number: 5623077
    Abstract: The present invention relates particularly to novel imidazole based nitrogen-sulfur ligands that are suitable for complexing with a radionuclide, and are useful as general imaging agents for diagnostic purposes.
    Type: Grant
    Filed: April 10, 1995
    Date of Patent: April 22, 1997
    Assignee: Mallinckrodt Medical, Inc.
    Inventors: Raghavan Rajagopalan, Ananthachari Srinivasan
  • Patent number: 5618513
    Abstract: A method for radiolabelling peptides using polyaminocarboxylate ligands having suitable protecting groups such that they can be added to peptides by standard solid phase or solution phase peptide synthetic chemistry and can be deproteced using standard cleavage/deprotection reagents and produce the peptide/chelate conjugate as a high purity mono-addition product is provided. The cleaved and deprotected ligand-peptide molecules can then be labeled with lanthanide or actinide radionuclides. The protected polyaminocarboxylate ligands form mono-anhydrides or mono-active esters under solid phase or solution phase conditions and permit only the desired monoaddition chelate-peptide conjugate to be formed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 8, 1997
    Assignee: Mallinckrodt Medical, Inc.
    Inventor: Ananthachari Srinivasan
  • Patent number: 5616692
    Abstract: Chelated radionuclide compositions are provided for conjugation to polypeptides and carbohydrates. The resulting conjugates may be used in diagnosis and therapy.
    Type: Grant
    Filed: May 8, 1995
    Date of Patent: April 1, 1997
    Assignee: NeoRx Corporation
    Inventors: Alan R. Fritzberg, Sudhakar Kasina, Tripuraneni N. Rao, Jean-Luc VanderHeyden, Ananthachari Srinivasan